The issue: Neurodegenerative diseases affect over a billion people worldwide; the human and economic cost of diseases like Fronto Temporal Dementia, Motor Neurone Disease (ALS, MND), Alzheimer’s, Parkinson’s and MS is huge.

The company: Nevrargenics’ technology is based on 19 years of world leading research at Durham and Aberdeen Universities and represents a major step-change in RAR-M based drug development. Its lead drug candidate is unique in that in modelling it indicates a potential for neurorepair (reversing disease). Nevrargenics’ vast IP library represents a new era in RAR-M based drug development and offers huge promise for ground-breaking progress in disease treatment.

Funding plan: The company was incorporated in the UK and technology transferred in 2019. Since then, Nevrargenics has raised equity of £0.75m and is now seeking £5m to fund manufacturing and trials for its lead drug, and second-generation drug development. EIS investment tax relief is available.

Value opportunity: The UK Regulator MHRA has green-lighted Phase I/IIa trials meaning that human results will be available within a year, providing a potentially very significant value creation/ inflection point. The company is already on the radar screen of a range of Big Pharma, which could be the ultimate partners in drug development and commercialisation.

Management: Management comprises Professor Andy Whiting, the company Chief Executive and a world leading chemist & scientist, supported by an experienced biology & pharmaceutical industry team.

Plus, recent news: Nevrargenics has secured a grant of $7.5 million (based on matched funding of $2.5 million) from the prestigious Funding Partnership, linked to the United Nations and the SDG goals, a testament to their progress.

We would be delighted to have you there if this might be of interest. Please do let us know if you will be attending or you can register for the event here.